Johnson & Johnson

November 6, 2013
Johnson & Johnson (J&J) will pay more than $2.2 billion to resolve criminal and civil liability allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and, payment of kickbacks to physicians and to pharmacy providers, the U.S. Department of...